# Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

> **NCT00673439** · PHASE2 · TERMINATED · sponsor: **University of Louisville** · enrollment: 3 (actual)

## Conditions studied

- Heparin-Induced Thrombocytopenia

## Interventions

- **DRUG:** fondaparinux
- **DRUG:** warfarin

## Key facts

- **NCT ID:** NCT00673439
- **Lead sponsor:** University of Louisville
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** study terminated due to low accrual
- **Last updated:** 2019-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00673439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00673439, "Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00673439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*